End-of-day quote
Dhaka S.E.
06:00:00 2024-04-24 pm EDT
|
5-day change
|
1st Jan Change
|
759.9
BDT
|
-3.00%
|
|
-5.06%
|
-37.61%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
96,514
|
90,910
|
128,602
|
144,239
|
139,689
|
87,158
|
-
|
-
|
Enterprise Value (EV)
1 |
94,544
|
87,797
|
126,534
|
150,822
|
139,689
|
87,158
|
87,158
|
87,158
|
P/E ratio
|
23.4
x
|
20.6
x
|
23.1
x
|
26.4
x
|
59.7
x
|
21.4
x
|
16.6
x
|
11.9
x
|
Yield
|
0.92%
|
1.39%
|
1.1%
|
1.11%
|
-
|
0.7%
|
0.91%
|
2.53%
|
Capitalization / Revenue
|
4.23
x
|
3.68
x
|
4.29
x
|
4.64
x
|
-
|
2.36
x
|
2.06
x
|
1.8
x
|
EV / Revenue
|
4.23
x
|
3.68
x
|
4.29
x
|
4.64
x
|
-
|
2.36
x
|
2.06
x
|
1.8
x
|
EV / EBITDA
|
15.8
x
|
13.3
x
|
16.3
x
|
18.7
x
|
-
|
11.6
x
|
9.31
x
|
7.57
x
|
EV / FCF
|
40.5
x
|
43.2
x
|
69
x
|
-20.4
x
|
-
|
-64
x
|
32.6
x
|
16.9
x
|
FCF Yield
|
2.47%
|
2.32%
|
1.45%
|
-4.9%
|
-
|
-1.56%
|
3.06%
|
5.9%
|
Price to Book
|
4.72
x
|
3.8
x
|
5
x
|
4.58
x
|
-
|
2.57
x
|
2.26
x
|
1.93
x
|
Nbr of stocks (in thousands)
|
114,696
|
114,696
|
114,696
|
114,696
|
114,696
|
114,696
|
-
|
-
|
Reference price
2 |
841.5
|
792.6
|
1,121
|
1,258
|
1,218
|
759.9
|
759.9
|
759.9
|
Announcement Date
|
11/28/19
|
11/29/20
|
10/23/21
|
11/27/22
|
11/14/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
22,809
|
24,675
|
29,971
|
31,071
|
-
|
36,958
|
42,308
|
48,326
|
EBITDA
1 |
6,091
|
6,814
|
7,892
|
7,696
|
-
|
7,509
|
9,362
|
11,509
|
EBIT
1 |
5,290
|
5,859
|
6,863
|
6,527
|
-
|
6,281
|
7,994
|
10,050
|
Operating Margin
|
23.19%
|
23.74%
|
22.9%
|
21.01%
|
-
|
16.99%
|
18.89%
|
20.8%
|
Earnings before Tax (EBT)
1 |
5,154
|
5,878
|
6,777
|
6,123
|
-
|
5,088
|
6,568
|
9,171
|
Net income
1 |
3,756
|
4,012
|
5,062
|
5,111
|
2,339
|
4,070
|
5,254
|
7,337
|
Net margin
|
16.46%
|
16.26%
|
16.89%
|
16.45%
|
-
|
11.01%
|
12.42%
|
15.18%
|
EPS
2 |
36.02
|
38.48
|
48.54
|
47.68
|
20.40
|
35.50
|
45.80
|
64.00
|
Free Cash Flow
1 |
2,382
|
2,106
|
1,864
|
-7,061
|
-
|
-1,362
|
2,671
|
5,146
|
FCF margin
|
10.44%
|
8.54%
|
6.22%
|
-22.73%
|
-
|
-3.69%
|
6.31%
|
10.65%
|
FCF Conversion (EBITDA)
|
39.11%
|
30.91%
|
23.62%
|
-
|
-
|
-
|
28.53%
|
44.71%
|
FCF Conversion (Net income)
|
63.43%
|
52.5%
|
36.82%
|
-
|
-
|
-
|
50.84%
|
70.14%
|
Dividend per Share
2 |
7.724
|
11.05
|
12.32
|
14.00
|
-
|
5.300
|
6.900
|
19.20
|
Announcement Date
|
11/28/19
|
11/29/20
|
10/23/21
|
11/27/22
|
11/14/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
6,583
|
-
|
-
|
-
|
-
|
Net Cash position
|
1,970
|
3,113
|
2,068
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
0.8554
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
2,382
|
2,106
|
1,864
|
-7,061
|
-
|
-1,362
|
2,671
|
5,146
|
ROE (net income / shareholders' equity)
|
22%
|
19.9%
|
21.3%
|
18.5%
|
-
|
12%
|
13.6%
|
16.2%
|
ROA (Net income/ Total Assets)
|
16.3%
|
14.8%
|
-
|
13.3%
|
-
|
7.7%
|
8.9%
|
11.9%
|
Assets
1 |
23,012
|
27,031
|
-
|
38,394
|
-
|
52,857
|
59,034
|
61,655
|
Book Value Per Share
2 |
178.0
|
209.0
|
224.0
|
274.0
|
-
|
296.0
|
337.0
|
394.0
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
1,849
|
2,493
|
4,423
|
10,070
|
-
|
-
|
-
|
-
|
Capex / Sales
|
8.11%
|
10.1%
|
14.76%
|
32.41%
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/28/19
|
11/29/20
|
10/23/21
|
11/27/22
|
11/14/23
|
-
|
-
|
-
|
Last Close Price
759.9
BDT Average target price
1,109
BDT Spread / Average Target +45.94% Consensus |
1st Jan change
|
Capi.
|
---|
| -37.61% | 794M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|